Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says. Though most people recover from the ...

The data cover from September 6, 2021, to March 10 ... that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

Over the previous few years, every mRNA-based booster I’d gotten — the ones made by Moderna and Pfizer ... occurring in only 6 percent of people after a second dose. Other side effects ...

Moderna MRNA shares soared 11.7% in the last trading session to close at $47.53. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Moderna appears attractive compared to the industry. Going by the price/sales (P/S) ratio, the company’s shares currently trade at 3.09, trailing 12-month sales value, lower than 6.61 for the ...

Moderna has reported preliminary clinical ... and there is a measure of sustained response over a six-month period post-booster, albeit a reduction in absolute antibody level compared to one ...

And while it does not usually cause severe illness in healthy adults and children, some people with RSV infection, especially older adults and infants younger than 6 months of age, can become very ...

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed ... 19 as we enter the winter months," according to Moderna's chief executive Stéphane ...